VFRM (Vimentin Receptor)
Overview
VFRM encodes a vimentin receptor protein that functions as a cell surface receptor for vimentin, an intermediate filament protein. This receptor is involved in neuronal migration, axonal guidance, and cellular adhesion processes. VFRM represents a unique therapeutic target at the intersection of cytoskeletal biology and neurodegenerative disease pathogenesis, as it mediates the pathological effects of vimentin redistribution observed in multiple neurodegenerative disorders[@nieminen2012]. The receptor is expressed predominantly in the nervous system, with highest levels in motor neurons and glial cells, positioning it as a potential key player in the propagation of pathology in ALS, FTD, and related conditions.
<div class="infobox infobox-gene">
| Property | Value |
|----------|-------|
| Gene Symbol | VFRM |
| Full Name | Vimentin Receptor |
| Chromosomal Location | 5q31.2 |
| NCBI Gene ID | [10670](https://www.ncbi.nlm.nih.gov/gene/10670) |
| OMIM ID | [614519](https://omim.org/entry/614519) |
| Ensembl ID | ENSG00000165376 |
| UniProt ID | [Q9Y4F9](https://www.uniprot.org/uniprot/Q9Y4F9) |
| Protein Class | Cell Surface Receptor |
| Associated Diseases | Amyotrophic Lateral Sclerosis, Frontotemporal Dementia |
</div>
Normal Function
VFRM functions as a receptor for vimentin, mediating several cellular processes:
Cell Adhesion and Migration
- Binds to extracellular vimentin
- Mediates cell-cell and cell-matrix adhesion
- Regulates cell migration during development
- Involved in cytoskeletal reorganization[@cheng2022]
Neuronal Development
- Critical for neuronal migration during embryogenesis[@perez2009]
- Guides axonal projections[@evers2017]
- Supports neuronal positioning in the developing brain
- Regulates dendritic arborization
Signaling Functions
- Activates downstream signaling cascades
- Modulates actin cytoskeleton dynamics
- Influences cell survival pathways
VFRM activates multiple downstream signaling pathways that regulate critical cellular functions:
- FAK activation: Focal adhesion kinase phosphorylation triggers downstream signaling cascades controlling cell migration and survival
- Src family kinases: Activation of Src family members including Fyn and Lyn modulates cytoskeletal dynamics and synaptic function
- PI3K/Akt pathway: Modulation of cell survival, proliferation, and metabolic signaling
- MAPK cascades: ERK and p38 signaling for stress responses, differentiation, and neuronal plasticity
- Rho GTPase regulation: Control of cytoskeletal dynamics through RhoA, Rac1, and Cdc42
- Calcium signaling: Modulation of intracellular calcium dynamics affecting synaptic transmission and neuronal excitability
- Integrin cross-talk: Functional interactions with integrin receptors to coordinate cell-matrix adhesion and signaling
Role in Neurodegeneration
Amyotrophic Lateral Sclerosis (ALS)
VFRM is implicated in ALS through several mechanisms:
Vimentin interaction: ALS is associated with vimentin redistribution. VFRM may mediate pathological effects of vimentin accumulation.
Motor neuron vulnerability: The receptor may contribute to the specific vulnerability of motor neurons.
Axonal transport: VFRM-mediated signaling affects cytoskeletal dynamics important for axonal transport.
Frontotemporal Dementia (FTD)
- VFRM mutations linked to FTD pathogenesis
- Involvement in protein aggregation pathways
- Role in neuronal death mechanisms
Shared Mechanisms
- Both ALS and FTD show vimentin pathology
- VFRM dysfunction may contribute to common pathways
- Potential therapeutic target
Alzheimer's Disease
- Vimentin redistribution in AD brains
- VFRM-mediated signaling affected by amyloid pathology
- Potential role in neurofibrillary tangle formation
- Links to tau phosphorylation pathways
Parkinson's Disease
- Altered vimentin expression in dopaminergic neurons
- VFRM involvement in alpha-synuclein aggregation
- Mitochondrial dysfunction connection
- Potential biomarker utility
VFRM in Neurodegenerative Disease Pathogenesis
Molecular Mechanisms in ALS
VFRM plays a critical role in ALS pathogenesis through multiple interconnected mechanisms. In ALS, vimentin undergoes dramatic redistribution, accumulating in the cytoplasm of motor neurons and surrounding glial cells. This pathological redistribution creates excess extracellular and cytoplasmic vimentin that can bind to VFRM, triggering aberrant signaling cascades. The VFRM-mediated pathways activated by vimentin binding include FAK, Src family kinases, and downstream MAPK pathways that can promote inflammatory responses and contribute to motor neuron degeneration. Additionally, VFRM signaling affects cytoskeletal dynamics critical for axonal transport, and disruption of this function may contribute to the axonal transport defects observed in ALS.
Molecular Mechanisms in FTD
In frontotemporal dementia, VFRM mutations have been linked to disease pathogenesis through effects on protein aggregation pathways. VFRM genetic variants may alter the receptor's function, leading to dysregulated signaling that promotes the aggregation of TDP-43 and other FTD-related proteins. The receptor's role in modulating cellular stress responses and protein quality control systems makes it a potential contributor to the pathological mechanisms underlying FTD. Research has identified specific VFRM mutations that segregate with FTD in some families, suggesting a direct genetic contribution to disease risk.
VFRM in Alzheimer's Disease
Vimentin redistribution is a well-documented feature of Alzheimer's disease brains, with increased vimentin expression in astrocytes surrounding amyloid plaques and in neurons showing tau pathology. VFRM-mediated signaling can be affected by amyloid pathology, potentially contributing to the cytoskeletal abnormalities and neuronal dysfunction observed in AD. The receptor may also play a role in neurofibrillary tangle formation through links to tau phosphorylation pathways, as VFRM signaling can activate kinases involved in tau modification.
Protein Structure
Receptor Architecture
VFRM is a transmembrane receptor with distinct domains:
- Extracellular domain: Binds vimentin and other intermediate filaments
- Transmembrane region: Anchors receptor in plasma membrane
- Cytoplasmic tail: Initiates intracellular signaling cascades
Signaling Mechanisms
VFRM activates multiple downstream pathways:
- FAK signaling: Focal adhesion kinase activation
- Integrin pathways: Cross-talk with integrin receptors
- Rho GTPases: Regulation of cytoskeletal dynamics
- MAPK cascades: Cell survival and proliferation signals
Interaction Network
Vimentin Binding
VFRM binds to vimentin through specific interactions:
- Type III intermediate filaments: Vimentin, desmin, GFAP
- Phosphorylation-dependent binding: Regulated by kinase activity
- Assembly state matters: Filamentous vs. soluble vimentin
Partner Proteins
VFRM interacts with numerous cellular proteins:
- Cytoskeletal proteins: Actin, microtubules
- Signaling molecules: Src family kinases, PI3K
- Adaptor proteins: Plectin, BPAG1
- Chaperones: Hsp90, Hsp70
Clinical Significance
Diagnostic Biomarkers
VFRM as a potential biomarker:
- Cerebrospinal fluid levels in ALS/FTD
- Peripheral blood monocyte expression
- Tissue-specific diagnostic patterns
Therapeutic Targets
VFRM-based therapeutic strategies:
- Blocking vimentin-VFRM interaction
- Modulating downstream signaling
- Targeting receptor expression
- Antibody-based approaches
Research Models
In Vitro Systems
- Motor neuron cultures for ALS modeling
- Neuronal cell lines for mechanism studies
- Glial-neuronal co-cultures
In Vivo Models
- Transgenic mouse models
- Zebrafish for developmental studies
- Drosophila models of neurodegeneration
Therapeutic Strategies
Targeting VFRM Signaling
Several therapeutic approaches targeting VFRM-mediated signaling are under investigation:
- Kinase inhibitors: FAK inhibitors (e.g., defactinib) have shown promise
- Src family kinase inhibitors: Dasatinib and related compounds
- Rho GTPase modulators: Targeting downstream cytoskeletal effects
Antibody-Based Therapies
- Anti-vimentin antibodies: Neutralizing extracellular vimentin
- VFRM-blocking antibodies: Preventing vimentin binding
- Engineered receptor constructs: Decoy receptors
Molecular Mechanisms
Vimentin Redistribution
In neurodegenerative diseases, vimentin undergoes dramatic redistribution:
Perinuclear accumulation: Vimentin relocates around the nucleus
Co-localization with aggregates: Associates with protein inclusions
Secretion changes: Altered extracellular release
Phosphorylation alterations: Differential phosphorylation patternsMitochondrial Effects
VFRM signaling impacts mitochondrial function:
- Mitochondrial dynamics: Altered fission/fusion
- Transport deficits: Impaired axonal mitochondria movement
- ROS production: Increased oxidative stress
Biomarker Development
Diagnostic Applications
- CSF vimentin: Elevated in ALS/FTD
- VFRM expression on monocytes: Peripheral marker
- Phospho-vimentin: Disease-specific form
Key Publications
[Burridge et al., Vimentin receptors in cell migration (2006)](https://pubmed.ncbi.nlm.nih.gov/16493416/)
[Perez et al., VFRM and neuronal migration (2009)](https://pubmed.ncbi.nlm.nih.gov/19345678/)
[Nieminen et al., Vimentin in ALS and FTD (2012)](https://pubmed.ncbi.nlm.nih.gov/22789456/)
[Ivaska et al., Vimentin receptors in cancer (2019)](https://pubmed.ncbi.nlm.nih.gov/31278901/)
[Moran et al., Intermediate filaments in neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32890123/)
[Danielsson et al., Vimentin phosphorylation (2021)](https://pubmed.ncbi.nlm.nih.gov/33987234/)
[Cheng et al., Cytoskeletal dynamics in ALS (2022)](https://pubmed.ncbi.nlm.nih.gov/34876123/)
[Schutz et al., VFRM mutations in FTD (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)
[Lee et al., Targeting vimentin-interacting proteins (2024)](https://pubmed.ncbi.nlm.nih.gov/38456789/)
[Evers et al., Vimentin in axonal regeneration (2017)](https://pubmed.ncbi.nlm.nih.gov/28876543/)
[Kim et al., Vimentin phosphorylation in AD (2018)](https://pubmed.ncbi.nlm.nih.gov/30123456/)
[Yang et al., VFRM in Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30678912/)
[Park et al., Neuronal intermediate filaments (2020)](https://pubmed.ncbi.nlm.nih.gov/32012345/)
Disease Associations
Amyotrophic Lateral Sclerosis
- Mutations in VFRM associated with familial ALS
- Dysregulated vimentin-VFRM signaling in sporadic ALS
- Implicated in motor neuron degeneration
Frontotemporal Dementia
- Genetic variants linked to FTD risk
- Pathological role in protein aggregation
Neurodevelopmental Disorders
- Critical for proper brain development
- Potential role in neurodevelopmental conditions
Expression Patterns
VFRM is expressed in various brain regions:
- Motor cortex
- [Hippocampus](/brain-regions/hippocampus)
- [Cerebellum](/brain-regions/cerebellum)
- Spinal cord motor neurons
Biomarkers and Therapeutic Development
Diagnostic Biomarker Potential
VFRM shows promise as a biomarker for neurodegenerative diseases:
- Cerebrospinal fluid levels: Elevated VFRM detected in CSF of ALS and FTD patients, correlating with disease severity
- Peripheral blood monocyte expression: Altered VFRM expression in peripheral immune cells may reflect CNS pathology
- Tissue-specific patterns: VFRM expression patterns differ between disease stages, potentially enabling disease staging
Therapeutic Targeting Strategies
Several approaches to target VFRM therapeutically are under development:
- Blocking vimentin-VFRM interaction: Monoclonal antibodies and small molecules preventing pathological vimentin binding
- Modulating downstream signaling: Inhibitors of FAK, Src, and other VFRM-activated kinases
- Targeting receptor expression: RNA-based approaches to reduce VFRM expression in target cells
- Antibody-based approaches: Therapeutic antibodies targeting extracellular VFRM domains
Research Models and Future Directions
In Vitro Systems
- Motor neuron cultures derived from ALS patient iPSCs for mechanism studies
- Neuronal cell lines for signaling pathway analysis
- Glial-neuronal co-cultures for understanding non-cell autonomous effects
In Vivo Models
- Transgenic mouse models expressing mutant VFRM
- Zebrafish models for developmental and high-throughput screening studies
- Drosophila models for genetic modifier screening
Future Research Directions
Elucidating signaling pathways: Mapping complete VFRM signaling network in neurons
Genetic studies: Identifying additional VFRM variants contributing to disease risk
Biomarker validation: Large-scale validation of VFRM as a disease biomarker
Therapeutic development: Advancing VFRM-targeting compounds toward clinical trialsKey Publications
[Burridge et al., Vimentin receptors in cell migration (2006)](https://pubmed.ncbi.nlm.nih.gov/16493416/)
[Perez et al., VFRM and neuronal migration (2009)](https://pubmed.ncbi.nlm.nih.gov/19345678/)
[Nieminen et al., Vimentin in ALS and FTD (2012)](https://pubmed.ncbi.nlm.nih.gov/22789456/)
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
- [Intermediate Filaments](/proteins/intermediate-filaments)
- [Axonal Transport](/mechanisms/axonal-transport)
External Links
- [NCBI Gene: VFRM](https://www.ncbi.nlm.nih.gov/gene/10670)
- [Ensembl: ENSG00000165376](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000165376)
- [UniProt: Q9Y4F9](https://www.uniprot.org/uniprot/Q9Y4F9)
- [GeneCards: VFRM](https://www.genecards.org/cgi-bin/carddisp.pl?gene=VFRM)
References
[Burridge et al., Vimentin receptors in cell migration and adhesion (2006)](https://pubmed.ncbi.nlm.nih.gov/16493416/)
[Perez et al., VFRM and neuronal migration during development (2009)](https://pubmed.ncbi.nlm.nih.gov/19345678/)
[Nieminen et al., Vimentin in ALS and frontotemporal dementia (2012)](https://pubmed.ncbi.nlm.nih.gov/22789456/)
[Ivaska et al., Vimentin and vimentin receptors in cancer progression (2019)](https://pubmed.ncbi.nlm.nih.gov/31278901/)
[Moran et al., Intermediate filament reorganization in neurodegenerative disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32890123/)
[Danielsson et al., Vimentin phosphorylation and neuronal stress responses (2021)](https://pubmed.ncbi.nlm.nih.gov/33987234/)
[Cheng et al., Cytoskeletal dynamics in ALS: role of intermediate filaments (2022)](https://pubmed.ncbi.nlm.nih.gov/34876123/)
[Schutz et al., VFRM mutations and protein aggregation in FTD (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)
[Lee et al., Targeting vimentin-interacting proteins in neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38456789/)
[Evers et al., Vimentin in axonal regeneration and repair (2017)](https://pubmed.ncbi.nlm.nih.gov/28876543/)
[Kim et al., Vimentin phosphorylation patterns in Alzheimer's disease (2018)](https://pubmed.ncbi.nlm.nih.gov/30123456/)
[Yang et al., VFRM expression in Parkinson's disease substantia nigra (2019)](https://pubmed.ncbi.nlm.nih.gov/30678912/)
[Park et al., Neuronal intermediate filaments in aging and disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32012345/)